Journal article
Efficacy and safety of adjuvant systemic therapies in trial non-eligible resected stages III and IV melanoma patients
Abstract
BACKGROUND: Adjuvant immunotherapy and targeted therapy are now the standard of care for patients with resected stage IIIA-IV melanoma. However, little is known regarding its efficacy in real-world patients who were not represented in these landmark trials.
METHODS: This retrospective study included all patients with resected stage IIIA-IV melanoma who received adjuvant systemic therapy between January 1 2018 and December 31 2020, in two …
Authors
Alsadiq S; Kartolo A; McWhirter E; Hopman W; Baetz T
Journal
Melanoma Management, Vol. 12, No. 1,
Publisher
Taylor & Francis
Publication Date
December 31, 2025
DOI
10.1080/20450885.2025.2461963
ISSN
2045-0885